Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Abstract
Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of TGN1412, a novel superagonist anti-CD28 monoclonal antibody that directly stimulates T cells. Within 90 minutes after receiving a single intravenous dose of the drug, all six volunteers had a systemic inflammatory response characterized by a rapid induction of proinflammatory cytokines and accompanied by headache, myalgias, nausea, diarrhea, erythema, vasodilatation, and hypotension. Within 12 to 16 hours after infusion, they became critically ill, with pulmonary infiltrates and lung injury, renal failure, and disseminated intravascular coagulation. Severe and unexpected depletion of lymphocytes and monocytes occurred within 24 hours after infusion. All six patients were transferred to the care of the authors at an intensive care unit at a public hospital, where they received intensive cardiopulmonary support (including dialysis), high-dose methylprednisolone, and an anti-interleukin-2 receptor antagonist antibody. Prolonged cardiovascular shock and acute respiratory distress syndrome developed in two patients, who required intensive organ support for 8 and 16 days. Despite evidence of the multiple cytokine-release syndrome, all six patients survived. Documentation of the clinical course occurring over the 30 days after infusion offers insight into the systemic inflammatory response syndrome in the absence of contaminating pathogens, endotoxin, or underlying disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although the solid phase assay does not replicate in vivo presentation of TGN1412, which is not fully understood, it does induce substantial cytokine release equivalent to that reported in trial volunteers.”
From Severity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release (2013) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“In 2006, a life-threatening 'cytokine storm', not predicted by pre-clinical safety testing, rapidly occurred in all six healthy volunteers during the phase I clinical trial of the CD28 superagonist monoclonal antibody (mAb) TGN1412.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“One of the most striking features of the TGN1412-mediated 'cytokine storm' observed in humans was substantial TNF-a release within the first hour of infusion followed by dramatic increases in IFN-g, IL-2, IL-6, IL-8 and IL-10 plasma concentrations within 4 h (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“Concentrations of TNF-a measured by ELISA in culture supernatants collected 24 h after in vitro TGN1412 stimulation were also consistent with the peak concentrations reported in trial volunteers, with the considerable caveat that a comparison is being made between an in vitro system and an in vivo response.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“However, despite similar in vitro expression kinetics for IFN-g following TGN1412 stimulation, the concentrations of IFN-g were far lower than TNF-a responses in vitro, and an order of magnitude lower than concentrations of IFN-g predicted from in vivo responses in trial participants (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“10.1073/pnas.0501997102”
Cited work 10.1073/pnas.0501997102 · retracted 2009-07-09 · notice 10.1073/pnas.0906977106 · this paper published 2006-09-07
Citations
Cites
1 retracted
Gon, Y., Wood, M. R., Kiosses, W. B., Jo, E., Sanna, M. G., Chun, J., & Rosen, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501997102 · Cited by 128
RetractedBone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Bernard, G. R., Artigas, A., Brigham, K. L., Carlet, J., Falke, K., Hudson, L., Lamy, M., Legall, J. R., Morris, A., & Spragg, R. (1994) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.149.3.7509706 · Cited by 6,746
Sepsis-Induced Apoptosis Causes Progressive Profound Depletion of B and CD4+ T Lymphocytes in Humans
Hotchkiss, R. S., Tinsley, K. W., Swanson, P. E., Schmieg, R. E., Hui, J. J., Chang, K. C., Osborne, D. F., Freeman, B. D., Cobb, J. P., Buchman, T. G., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6952 · Cited by 934
Clinical risks for development of the acute respiratory distress syndrome.
Hudson, L. D., Milberg, J. A., Anardi, D., & Maunder, R. J. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.2.7842182 · Cited by 890
Brivet, F. G., Kleinknecht, D. J., Loirat, P., & Landais, P. J. M. (1996) · Critical Care Medicine · doi:10.1097/00003246-199602000-00003 · Cited by 879
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051060 · Cited by 203
Cited by
Items 801–900 of 2,162
Buckley, L. A., Benson, K. A., Davis-Bruno, K. L., Dempster, M., Finch, G. L., Harlow, P., Haggerty, H. G., Hart, T. K., Kinter, L. B., Leighton, J. K., et al. (2008) · International Journal of Toxicology · doi:10.1080/10915810802367016 · Cited by 28
“ical toxicity studies? In light of the serious adverse reactions reported for TGN1412 (Suntharalingam et al. 2006), there was some concern regarding the drug’s stimulating effect on the immune system.”
BackgroundDiscordant biological and toxicological species responses to TLR3 activation
Mitchell, W. M., Nicodemus, C. F., Carter, W. A., Horvath, J. C., & Strayer, D. R. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.12.006 · Cited by 27
Animal extrapolation in preclinical studies: An analysis of the tragic case of TGN1412
Lemoine, M. (2016) · Studies in History and Philosophy of Science Part C Studies in History and Philosophy of Biological and Biomedical Sciences · doi:10.1016/j.shpsc.2016.12.004 · Cited by 28
First-in-human dose: current status review for better future perspectives
Mishra, A., Sarangi, S. C., & Reeta, K. H. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-02924-x · Cited by 27
Selenium‐Containing Nanocomplexes Achieve Dual Immune Checkpoint Blockade for NK Cell Reinvigoration
Xianyu, B., Pan, S., Gao, S., Xu, H., & Li, T. (2023) · Small · doi:10.1002/smll.202306225 · Cited by 28
Schwameis, R., Eder, S., Pietschmann, H., Fischer, B. E., Mascher, H. J., Tzotzos, S. J., Fischer, H., Lucas, R., Zeitlinger, M. A., & Hermann, R. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.203 · Cited by 31
T-cell co-stimulatory blockade in transplantation: two steps forward one step back!
Riella, L. V., & Sayegh, M. H. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.845661 · Cited by 31
Engineering therapeutic antibodies for patient safety: tackling the immunogenicity problem
Ulitzka, M., Carrara, S. C., Grzeschik, J., Kornmann, H., Hock, B. M., & Kolmar, H. (2020) · Protein Engineering Design and Selection · doi:10.1093/protein/gzaa025 · Cited by 32
Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives
Heitmann, J. S., Pflügler, M., Jung, G., & Salih, H. R. (2021) · Cancers · doi:10.3390/cancers13030549 · Cited by 32
“However, the clinical development of such BiCos was thereafter impacted largely by the so called “Tegenero incident”, the deleterious cytokine release after application of a—notably monospecific and thus not target cell-restricted—“superagonistic” CD28 antibody [45,46].”
BackgroundInfluentialImmune checkpoints in sepsis: New hopes and challenges
Liu, Y., Shou, S., & Chai, Y. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.1884247 · Cited by 34
“However, there was a tragedy that six healthy volunteers experienced septic shock and multiple organs dysfunction syndrome (MODS) induced by cytokines storm after receiving a single intravenous dose of TGN1412 [11].”
BackgroundInfluentialTaki, S., Matsuoka, K., Nishinaga, Y., Takahashi, K., Yasui, H., Koike, C., Shimizu, M., Sato, M., & Sato, K. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003036 · Cited by 34
VEGF: Potential therapy for renal regeneration
Chade, A. (2011) · F1000 Medicine Reports · doi:10.3410/m4-2 · Cited by 29
“Nevertheless, caution is required in relation to immunemodulating therapy in the aftermath of the anti-CD28 monoclonal antibody trial [50], particularly given the very limited clinical experience with mesenchymal stem cells in critically ill patients to date [24].”
BackgroundTherapeutic Potential of Regulatory T cells in Autoimmune Disorders
Fessler, J., Felber, A., Duftner, C., & Dejaco, C. (2013) · BioDrugs · doi:10.1007/s40259-013-0026-5 · Cited by 31
“The most prominent example of a Treg-based therapy that was successful in rodents but resulted in a fatal outcome in humans was the CD28 superagonist antibody TGN1412 [73].”
Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation
Adler, A. J., & Vella, A. T. (2013) · OncoImmunology · doi:10.4161/onci.22837 · Cited by 29
Immunotherapy for liver tumors: present status and future prospects
Matar, P., Alaniz, L. D., Rozados, V. R., Aquino, J. B., Malvicini, M., Atorrasagasti, C., Gidekel, M., Silva, M., Scharovsky, O. G., & Mazzolini, G. D. (2009) · Journal of Biomedical Science · doi:10.1186/1423-0127-16-30 · Cited by 32
ICH Guidelines: Inception, Revision, and Implications for Drug Development
Wang, T., Jacobson‐Kram, D., Pilaro, A. M., Lapadula, D. M., Jacobs, A. C., Brown, P. C., Lipscomb, J. C., & McGuinn, W. D. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq286 · Cited by 31
Leggat, J. A., Gibbons, D. L., Haque, S. F. Y., Smith, A. L., Wells, J. W., Choy, K. J., Lloyd, C. M., Hayday, A., & Noble, A. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.08.011 · Cited by 31
“This might also explain the severe inflammatory reactions to superagonistic CD28 antibody seen in human beings but not laboratory animals.(23) Our concept of innate, or nonspecific, memory is clearly supported by the observation that CD8 Tms expanded by cytokines alone release IFN-g with the kinetics and quantity of e…”
Antibody-Based Immunotherapy of Solid Cancers: Progress and Possibilities
Nicodemus, C. F. (2015) · Immunotherapy · doi:10.2217/imt.15.57 · Cited by 32
Kizhedath, A., Wilkinson, S. C., & Glassey, J. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1876-7 · Cited by 31
“The catastrophic TGN1412 clinical trial that resulted in multiple organ failure of six healthy volunteers reiterated the need for better preclinical safety testing.”
BackgroundInfluentialHussain, K., Hargreaves, C. E., Rowley, T. F., Sopp, J. M., Latham, K. V., Bhatta, P., Sherington, J., Cutler, R. M., Humphreys, D. P., Glennie, M. J., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00390 · Cited by 28
“In the first-in-man trial of TGN1412, rapid, life-threatening CRS was observed in healthy volunteers (6).”
BackgroundMethodAntibody engineering to develop new antirheumatic therapies
Isaacs, J. D. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2594 · Cited by 32
“A profound example of the consequences of FcγR binding was witnessed following the administration of TGN1412 to six healthy volunteers in a phase I clinical trial in 2006 [37].”
BackgroundICOS-LICOS interaction is critically involved in TGN1412-mediated T-cell activation
Weissmüller, S., Semmler, L. Y., Kalinke, U., Christians, S., Müller-Berghaus, J., & Waibler, Z. (2012) · Blood · doi:10.1182/blood-2011-12-401083 · Cited by 26
Abdel‐Rahman, S. A., Świderek, K., & Gabr, M. T. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00150d · Cited by 24
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity
Hérault, A., Mak, J., Cruz-Chuh, J. D., Dillon, M. A., Ellerman, D. A., Go, M., Cosino, E., Clark, R., Carson, E., Yeung, S., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03795-2 · Cited by 30
Poirier, N., Mary, C., Bas‐Bernardet, S. L., Daguin, V., Belarif, L., Chevalier, M., Hervouet, J., Minault, D., Ville, S., Charpy, V., et al. (2014) · mAbs · doi:10.4161/mabs.28375 · Cited by 28
“Eight years ago, administration of TGN1412, a superagonist anti-CD28 mAb, to healthy volunteers caused a dramatic accident in a Phase 1 trial due to an acute and severe cytokine release syndrome (CRS), which had not been predicted by current preclinical animal models.(16) Indeed, the target epitope of TGN1412 was the…”
BackgroundDeterminants of immunogenic response to protein therapeutics
Singh, S. K., Cousens, L. P., Álvarez, D., & Mahajan, P. B. (2012) · Biologicals · doi:10.1016/j.biologicals.2012.06.001 · Cited by 26
“leading to a near fatal cytokine storm in humans [15].”
BackgroundThe delicate balance of melanoma immunotherapy
Gyorki, D. E., Callahan, M. K., Wolchok, J. D., & Ariyan, C. E. (2013) · Clinical & Translational Immunology · doi:10.1038/cti.2013.5 · Cited by 36
In vitro assays supporting the safety assessment of immunomodulatory monoclonal antibodies
Brennan, F. R., & Kießling, A. (2017) · Toxicology in Vitro · doi:10.1016/j.tiv.2017.02.025 · Cited by 29
Kundapura, S. V., & Ramagopal, U. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-54623-y · Cited by 26
Alnefaie, A., & Albogami, S. M. (2020) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2020.08.024 · Cited by 28
“Some infectious and non-infectious diseases are associated with presentation of the cytokine storm; a drawback of some therapeutic intervention attempts is that this type of action is promoted (Suntharalingam et al., 2006).”
Davey, A. S., Call, M. E., & Call, M. J. (2020) · Cancers · doi:10.3390/cancers13010038 · Cited by 29
Welsh, B. T., Faucette, R., Bilic, S., Martin, C. J., Schürpf, T., Chen, D. J., Nicholls, S. B., Lansita, J. A., & Kalra, A. V. (2021) · International Journal of Toxicology · doi:10.1177/1091581821998945 · Cited by 28
“Furthermore, in a non-GLP pilot toxicology study in rats, we showed an improved preclinical safety profile for SRK-181 as compared to pan-TGFb inhibition.20 Our current work summarizes follow-up preclinical studies that support the clinical development of SRK-181.”
MethodInfluentialMercan, A., Uzun, S. T., Keleş, S., Hacıbeyoğlu, G., Yılmaz, R., & Reıslı, R. (2021) · The Korean journal of pain · doi:10.3344/kjp.2021.34.4.463 · Cited by 33
“Tests on Treg cell expansion in humans have been stopped due to life-threatening side effects [39].”
BackgroundMary, C., Coulon, F., Poirier, N., Dilek, N., Martinet, B., Blancho, G., & Vanhove, B. (2013) · mAbs · doi:10.4161/mabs.22697 · Cited by 27
“Such antibodies directed against the C”D basolateral domain of CD28 caused a dramatic accident in a Phase 1 trial in 2006.(14) Second, even when the target epitope lies outside the C”D domain of CD28, antibodies might cross-link CD28 and mimic its physiological role, which in the presence of antigen, is the reinforcem…”
BackgroundSuperagonistic CD28 Antibody Induces Donor-Specific Tolerance in Rat Renal Allografts
Azuma, H., Isaka, Y., Li, X., Hünig, T., Sakamoto, T., Nohmi, H., Takabatake, Y., Mizui, M., Kitazawa, Y., Ichimaru, N., et al. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02358.x · Cited by 28
“This type of cytokine release had not been observed in preclinical studies of TGN 1412 (6,7), and it is currently unclear whether the severe effects of this type of cytokine release in vivo in humans are caused by direct ligation of CD28 on T cells or by interaction with cell types not included in the preclinical in v…”
BackgroundImmunological intervention in human diseases
Ueno, H., Hawrylowicz, C. M., & Banchereau, J. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-59 · Cited by 26
The Expanding Role of Therapeutic Antibodies
Salemi, S., Marković, M., Martini, G., & D’Amelio, R. (2014) · International Reviews of Immunology · doi:10.3109/08830185.2013.863304 · Cited by 28
“Cytokine release reaction, which may be indistinguishable from anaphylactic reactions, even though it is generally observed at the first administration [25], may start 1–2 hours after the infusion with headache, rigors, lumbar myalgia, dyspnea and, in the most severe cases, may be followed by hypotension, tachycardia,…”
BackgroundFuture for biological therapy for uveitis
Rosenbaum, J. T. (2010) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e32833f00b3 · Cited by 26
Safety Issues Specific to Clinical Development of Protein Therapeutics
Haller, C., Cosenza, M., & Jt, S. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.158 · Cited by 26
Kitazawa, Y., Fujino, M., Sakai, T., Azuma, H., Kimura, H., Isaka, Y., Takahara, S., Hünig, T., Abe, R., & Li, X. (2008) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2008.01.004 · Cited by 28
Nouveau, L., Buatois, V., Cons, L., Chatel, L., Pontini, G., Pleche, N., & Ferlin, W. G. (2021) · European Journal of Immunology · doi:10.1002/eji.202149181 · Cited by 25
The Northwick Park tragedy ? protecting healthy volunteers in future first-in-man trials
Dowsing, T., & Kendall, M. J. (2007) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2007.00808.x · Cited by 25
Rethinking risk assessment for emerging technology first-in-human trials
Genske, A., & Engel, S. (2015) · Medicine Health Care and Philosophy · doi:10.1007/s11019-015-9660-7 · Cited by 26
“2003; Wilson 2009) and the serious injuries of participants of the antibody TGN1412 trial (Suntharalingam et al. 2006; Wood and Darbyshire 2006) have tragically illustrated how uncertainties about adverse events can translate into actual harm.”
BackgroundInfluentialNooh, M. M., Nookala, S., Kansal, R. G., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002057 · Cited by 25
Anti-CD28 Antibody-Initiated Cytokine Storm in Canines
Rosinski, S. L., Storb, R. F., Strong, R. K., Sale, G. E., Stone, D. M., Gewe, M. M., Friend, D. J., Abrams, V. K., Randolph‐Habecker, J., & Graves, S. S. (2015) · Transplantation Direct · doi:10.1097/txd.0000000000000516 · Cited by 25
“Development of CD28-mediated therapies for clinical use has been influenced by the well-publicized phase 1 clinical trial of an anti-CD28 superagonist mAb TGN1412 (CD28supermonoclonal antibody, TeGeneroAG).(23) All 6 volunteers treated with the antibody became critically ill because of a cytokine storm.”
BackgroundInfluentialNivolumab in combination with ipilimumab for the treatment of melanoma
Somasundaram, R., & Herlyn, M. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1093418 · Cited by 29
“In a Phase I clinical trial, the use of anti-CD28 to boost immune responses was abandoned as six of the eight volunteers developed a massive cytokine storm and severe adverse reactions within an hour of infusion of the agonistic antibody [27].”
BackgroundBird, S. M., Bailey, R. A., Grieve, A. P., & Senn, S. J. (2017) · Pharmaceutical Statistics · doi:10.1002/pst.1801 · Cited by 24
CD28: A New Drug Target for Immune Disease
Xia, S., Chen, Q., & Niu, B. (2019) · Current Drug Targets · doi:10.2174/1389450120666191114102830 · Cited by 27
Pulmonary immune responses against SARS-CoV-2 infection: harmful or not?
Guillon, A., Hiemstra, P. S., & Si‐Tahar, M. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06170-8 · Cited by 25
Vissers, M. F. J. M., Cohen, A. F., Van Gerven, J. M. A., & Groeneveld, G. J. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14480 · Cited by 25
Cytokine Drizzle—The Rationale for Abandoning “Cytokine Storm”
Stolarski, A. E., Kim, J., Zhang, Q., & Remick, D. G. (2021) · Shock · doi:10.1097/shk.0000000000001769 · Cited by 27
“Anti-CD28 (20) 6 3,350 CAR-T (mild) (4–8) 209 57 CAR-T (severe) (4–8) 36 4,809 Crohn’s disease (21–25) 423 5 Exercise (26–33) 92 11 JHR (34–38) 92 2,170 LPS—low dose* (39–41) 61 132 LPS—high dose (39–42) 83 497 Myxoma (43–46) 22 20 RA (11–17) 623 34 SARS CoV-2 (moderate) (47–55) 429 16 SARS CoV-2 (severe) (47–55) 331…”
Tang, K., & Nastoupil, L. J. (2021) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-21-2 · Cited by 26
“The risk of CRS is influenced by both pretreatment factors, such as tumor burden, and treatment-related factors such as the costimulatory domain of the CAR, dose of CAR T cells infused, and lymphodepletion.([18,19]) Treatment of CRS is guided by institutional policies and is mostly supportive.”
BackgroundInfluentialAldewereld, Z., Zhang, L. A., Urbano, A., Parker, R. S., Swigon, D., Banerjee, I., Gómez, H., & Clermont, G. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.794423 · Cited by 29
Giving monoclonal antibodies to healthy volunteers in phase 1 trials: is it safe?
Tranter, E., Peters, G., Boyce, M. J., & Warrington, S. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12096 · Cited by 26
Yver, A., Homery, M., Fuseau, E., et al. (2012) · Vox Sanguinis · doi:10.1111/j.1423-0410.2012.01603.x · Cited by 25
Co-stimulation and T cells as therapeutic targets
Gizinski, A. M., Fox, D. A., & Sarkar, S. (2010) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2009.12.015 · Cited by 25
“Indeed, administration of TGN1412, an anti-CD28 monoclonal antibody, to healthy human volunteers resulted in acute onset of cytokine storm and associated multi-organ failure (10).”
Jiang, H., & Chess, L. (2008) · Human Immunology · doi:10.1016/j.humimm.2008.08.279 · Cited by 25
The Path to Reactivation of Antitumor Immunity and Checkpoint Immunotherapy
Kim, H. J., & Cantor, H. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0153 · Cited by 31
Chowdhury, F. D., Johnson, P., Glennie, M. J., & Williams, A. P. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0070 · Cited by 26
“In particular, immunostimulatory antibodies are showing promise in enabling an individual’s own immune repertoire to mount a successful immune response specific against cancer; however, their use comes with a high risk of serious cytotoxicity as was notably encountered with the TeGenero TGN1412, anti-CD28 super-agonis…”
BackgroundKametani, Y., Katano, I., Miyamoto, A., Kikuchi, Y., Ito, R., Muguruma, Y., Tsuda, B., Habu, S., Tokuda, Y., Ando, K., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179239 · Cited by 29
D’Cruz, O. J., Qazi, S., Hwang, L., Ng, K., & Trieu, V. N. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s161905 · Cited by 29
Bending, D., & Lab), M. O. (. (2018) · Clinical & Experimental Immunology · doi:10.1111/cei.13194 · Cited by 28
“This trial, however, resulted in catastrophe, where all six volunteers given TGN1412 developed a ‘cytokine storm’ due to stimulation of a significant proportion of T cells [10].”
BackgroundWhatever happened to the Shwartzman phenomenon?
Chahin, A. B., Opal, J. M., & Opal, S. M. (2018) · Innate Immunity · doi:10.1177/1753425918808008 · Cited by 27
Rapid Desensitization in Immediate Hypersensitivity Reaction to Drugs
Junior, P. F. G.-B., Aun, M. V., Galvão, V. R., & Castells, M. (2015) · Current Treatment Options in Allergy · doi:10.1007/s40521-015-0060-2 · Cited by 25
Selection of human anti-CD28 scFvs from a T-NHL related scFv library using ribosome display
Rothe, A., Nathanielsz, A., Hosse, R. J., Oberhauser, F., von Strandmann, E. P., Engert, A., Hudson, P. J., & Power, B. E. (2007) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2007.05.012 · Cited by 25
How do we assure the quality of biological medicines?
Longstaff, C., Whitton, C. M., Stebbings, R., & Gray, E. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.09.010 · Cited by 27
“These calculations were, however, flawed because none of these doses produce any adverse effects in Cynomolgus macaques [ 28 ].”
BackgroundResultImmunology: A tolerant approach
Garber, K. (2014) · Nature · doi:10.1038/507418a · Cited by 28
Current Technologies and Future Perspectives in Immunotherapy towards a Clinical Oncology Approach
Adhikary, S., Pathak, S., Palani, V., Acar, A., Banerjee, A., Al-Dewik, N. I. E., Essa, M. M., Mohammed, S. G. A. A., & Qoronfleh, M. W. (2024) · Biomedicines · doi:10.3390/biomedicines12010217 · Cited by 31
“Activating stimulatory pathways may involve Theralizumab (TGN1412), a mAb agonist of CD28 known to interact with B7, which is a co-stimulatory molecule that activates T cells; hence, proliferated and differentiated T cells improve the antitumor immune response [49].”
BackgroundHow Biologics Have Changed the Drug Discovery Landscape
McGonigle, P. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061724-080811 · Cited by 32
Barcoded screening identifies nanocarriers for protein delivery to kidney
Wang, L., Zhou, W., Chen, H., Jia, X., Zheng, P., Jiang, H., Wu, M., Zhang, Y., Ding, Y., Peng, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56257-3 · Cited by 32
Imaging in targeted delivery of therapy to cancer
Dancey, G. J., Beǵent, R. H. J., & Meyer, T. (2009) · Targeted Oncology · doi:10.1007/s11523-009-0119-8 · Cited by 26
Adverse immunostimulation caused by impurities: The dark side of biopharmaceuticals
Reijers, J. A. A., Malone, K. E., Bajramovic, J. J., Verbeek, R., Burggraaf, J., & Moerland, M. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13938 · Cited by 26
“- - - - - - - - - - - - - - - - - - - - - - - - - e Creative Commons Attribution‐N d and is not used for commercial armacology published by John Wi administration, the trial participants developed multiorgan failure resulting from what was later termed a “cytokine storm”.(1)”
BackgroundMuscolini, M., Sajeva, A., Caristi, S., & Tuosto, L. (2011) · Immunology Letters · doi:10.1016/j.imlet.2011.01.011 · Cited by 27
CD28 and IL-4: two heavyweights controlling the balance between immunity and inflammation
Hünig, T., Lühder, F., Elflein, K., Gogishvili, T., Fröhlich, M., Guler, R., Cutler, A. J., & Brombacher, F. (2010) · Medical Microbiology and Immunology · doi:10.1007/s00430-010-0156-z · Cited by 30
“While the disastrous outcome of a firstin-man-study of a human CD28SA [33] has interrupted further development of CD28SA-based therapeuticals, these antibodies continue to be useful tools for the manipulation of the rodent immune system in attempts to study the contribution of immune deviation and/or Treg activation i…”
Subclinical CNS Inflammation as Response to a Myelin Antigen in Humanized Mice
Zayoud, M., Malki, K. E., Frauenknecht, K. B. M., Trinschek, B., Kloos, L., Karram, K., Wanke, F., Georgescu, J., Hartwig, U. F., Sommer, C., et al. (2013) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-013-9466-4 · Cited by 26
“Using humanized mice can therefore help to prevent unwanted side effects in testing of new drugs as it occurred in the trial of the superagonistic anti-CD28 monoclonal antibody TGN1412 (Suntharalingam et al. 2006).”
BackgroundTools for predicting the PK/PD of therapeutic proteins
Diao, L., & Meibohm, B. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1041917 · Cited by 27
“Toxicities of therapeutic proteins are usually related to exaggerated on-target pharmacology, which has been seen in an extreme case in the firstin-man clinical trial of a CD28 agonistic antibody [33].”
BackgroundDanilenko, D. M., & Wang, H. (2012) · Toxicologic Pathology · doi:10.1177/0192623311430237 · Cited by 24
“Subsequently, this acute illness following TGN1412 dosing was identified as cytokine release syndrome, as increased levels of TNF-a, IFN-g, and IL-2, -6, and -10 were detected in treated volunteers (Suntharalingam et al. 2006).”
BackgroundMidkine and multiple sclerosis
Takeuchi, H. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12499 · Cited by 24
Ryan, J. M., Wasser, J. S., Adler, A. J., & Vella, A. T. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1152256 · Cited by 24
“illustrated in Figure 1), such as headache, nausea, diarrhea, vasodilation, hypotension, and eventually (nonfatal) multiorgan failure.[162]”
BackgroundGülşen, A., Wedi, B., & Jappe, U. (2020) · Allergo Journal International · doi:10.1007/s40629-020-00127-5 · Cited by 27
Antibodies for HIV Treatment and Prevention: Window of Opportunity?
Huber, M., Olson, W. C., & Trkola, A. (2007) · Current topics in microbiology and immunology · doi:10.1007/978-3-540-72146-8_2 · Cited by 28
Cancer immunotherapy and its facilitation by nanomedicine
Sui, C., Wu, H., Li, X., Wang, Y., Wei, J., Yu, J., & Wu, X. (2024) · Biomarker Research · doi:10.1186/s40364-024-00625-6 · Cited by 28
“…is that excessive ICIs will easily cause adverse side effects like cytokine release syndrome or even immune-related adverse organ damage while a single ICI and low dose levels of ICIs are not enough to reverse the tumor immune-suppressive microenvironment and control tumors completely [232, 233].”
BackgroundIntegrating natural commensals and pathogens into preclinical mouse models
Rehermann, B., Graham, A. L., Masopust, D., & Hamilton, S. E. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01108-3 · Cited by 25
“However, TGN1412 induced life-threatening cytokine-release syndrome in healthy human volunteers during the phase I clinical trial 88 .”
Bispecific antibodies: Potential immunotherapies for HIV treatment
Fabozzi, G., Pegu, A., Koup, R. A., & Petrovas, C. (2018) · Methods · doi:10.1016/j.ymeth.2018.10.010 · Cited by 24
Mouse models in COVID-19 research: analyzing the adaptive immune response
Clever, S., & Volz, A. (2022) · Medical Microbiology and Immunology · doi:10.1007/s00430-022-00735-8 · Cited by 27
“While heavily infiltrating into tissues and organs with an overshooting cytokine secretion and cytotoxic activity, T cells can be the cause of a much more enhanced and severe disease course [78, 79].”
BackgroundEffectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer
Fransen, M. F., Cordfunke, R. A., Sluijter, M., van Steenbergen, M. J., Drijfhout, J. W., OSSENDORP, F. A., Hennink, W. E., & Melief, C. J. M. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.01.056 · Cited by 23
Burton, D. R., & Wilson, I. A. (2007) · Science · doi:10.1126/science.1148905 · Cited by 22
Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials
Hansen, A. R., Cook, N., Ricci, M., Razak, A. R. A., Tourneau, C. L., McKeever, K., Roskos, L. K., Dixit, R., Siu, L. L., & Hinrichs, M. J. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0008 · Cited by 24
Immuno-Oncology: The Third Paradigm in Early Drug Development
Martín-Liberal, J., Hierro, C., de Olza, M. O., & Rodon, J. A. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0471-4 · Cited by 25
Immune-Mediated Therapies for Liver Cancer
Aravalli, R. N., & Steer, C. J. (2017) · Genes · doi:10.3390/genes8020076 · Cited by 26
“However, when a single dose of TGN1412 was administered to six healthy volunteers, they all experienced severe cytokine release syndrome with multi-organ failure [144].”
BackgroundAgur, Z., Elishmereni, M., Foryś, U., & Kogan, Y. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1942 · Cited by 30
“These events shed some light on the immune-mediated cytokine storm, which leads to multi-organ failure in the absence of infection.(67) Even though there may have been several reasons for this mishap, we dare speculate that much of the drama could have been avoided by timely consulting the mathematical model and joini…”
BackgroundBrennan, F. R., Cauvin, A. J., Tibbitts, J., & Wolfreys, A. (2014) · Drug Development Research · doi:10.1002/ddr.21173 · Cited by 23
“This led to catastrophic systemic organ failure in the normal volunteers in the trial [Suntharalingam et al., 2006; Hunig, 2012] and provided a “wake-up call” to the industry in highlighting that some mAbs have a real potential for human toxicity.”
BackgroundInfluentialRestoring the balance: Harnessing regulatory T cells for therapy in rheumatoid arthritis
Flores‐Borja, F., Mauri, C., & Ehrenstein, M. R. (2008) · European Journal of Immunology · doi:10.1002/eji.200738107 · Cited by 23
Mehrishi, J. N., Szabó, M., & Bakács, T. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.02.078 · Cited by 26
Leach, M. W. (2013) · Toxicologic Pathology · doi:10.1177/0192623312451371 · Cited by 22
“This can have devastating consequences to the animal or human patient, as occurred in rare instances with immune responses to erythropoietin therapy resulting in aplastic anemia (Randolph et al. 1999; Verhelst et al. 2004).”
BackgroundJanus kinase inhibition in the treatment and prevention of graft-versus-host disease
Togni, E. D., Cole, O., & Abboud, R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1304065 · Cited by 24
Were monocytes responsible for initiating the cytokine storm in the TGN1412 clinical trial tragedy?
Sandilands, G. P., Wilson, M. R., Huser, C. A. M., Jolly, L., Sands, W. A., & McSharry, C. P. (2010) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2010.04264.x · Cited by 24
Ostrand‐Rosenberg, S., Horn, L. A., & Álvarez, J. A. G. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1677-5 · Cited by 24
“A phase I trial of superagonist mAb TGN1412 to CD28 created a cytokine storm (cytokine release syndrome) in all six volunteers [45].”
New and emerging treatment approaches to lupus
Haubitz, M. (2010) · Biologics · doi:10.2147/btt.s7581 · Cited by 22
“Interference with the co-stimulatory signals might have severe unexpected side effects as shown in a Phase I trial in 2006, where an agonistic monoclonal antibody to CD28 led to a cytokine release syndrome in all healthy subjects receiving the antibody.(29)”
BackgroundHarnessing the immune system for cancer therapy
Smith, E. L., Zamarin, D., & Lesokhin, A. M. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000128 · Cited by 27
Metadata
- Authors
- Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N.
- Affiliations
- Hammersmith Hospital (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-09-07
- Volume
- 355
- Issue
- 10
- Pages
- 1018-1028
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141989396
- Cited by
- 2,164
- References
- 18
- Citations by year
- 2026: 57 · 2025: 73 · 2024: 95 · 2023: 79 · 2022: 79 · 2021: 120 · 2020: 141 · 2019: 94 · 2018: 102 · 2017: 97 · 2016: 117 · 2015: 122 · 2014: 118 · 2013: 120 · 2012: 114
- FWCI
- 80.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- cytokine release syndrome, TGN1412, anti-CD28 monoclonal antibody, systemic inflammatory response syndrome, inflammatory cytokines, acute respiratory distress syndrome, disseminated intravascular coagulation, renal failure, drug-induced immunotoxicity
- MeSH terms
- Adult, Antibodies, Monoclonal, C-Reactive Protein, Critical Care, Double-Blind Method, Hemodynamics, Humans, Hypotension, Infusions, Intravenous, Leukopenia, Male, Multiple Organ Failure, Thrombocytopenia, Cytokines, CD28 Antigens, Disease Progression, APACHE, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.